Policy | March 14, 2022
Draft policy on medical devices released
Feedback and remarks of the industry and stakeholders are invited till the 25th of March 2022
Feedback and remarks of the industry and stakeholders are invited till the 25th of March 2022
Its technology-centric solutions enable hospitals to enhance operational efficiency and enable faster clinical decision making
Ritika has also extensively worked with clients such as WHO, GAVI Alliance, USAID, Gilead, Novartis, Sanofi Pasteur
He was earlier associated with leading industry players like Hindustan Unilever, TATA Communications, Dr. Lal Path Labs, Oncquest and Metropolis Healthcare
A total of 49 projects have been approved so far for 33 critical APIs with a committed investment of Rs 3,685 crore
The open-label, multicenter, randomized Phase 1 trial is designed to evaluate the safety and immunogenicity of experimental HIV trimer mRNA vaccines
Amit Jaju, Senior Managing Director, India in an interview with Thomas C Thottathil outlined the steps Indian pharma companies should follow to be compliant with global regulatory requirements
Lynparza is approved in the US, EU, Japan and several other countries for the treatment of patients with gBRCAm, HER2-negative, metastatic breast cancer previously treated with chemotherapy based on results from the OlympiAD Phase III trial
Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers releases guidelines for the scheme
Tislelizumab is now approved for seven indications in China
Subscribe To Our Newsletter & Stay Updated
